Fangjun J Wu

US Patent:

20030224039, Dec 4, 2003

Filed:

Mar 5, 2003

Appl. No.:

10/383004

Inventors:

Lawrence Boni - Monmouth Junction NJ, US
Brian Miller - Mercerville NJ, US
Fangjun Wu - Livingston NJ, US

Assignee:

Transave, Inc. - Monmouth Junction NJ

International Classification:

A61K031/704
A61K031/65
A61K031/4709
A61K009/127

US Classification:

424/450000, 514/037000, 514/312000, 514/152000

Abstract:

A method of preparing a liposomal bioactive agent comprising infusing an lipid-ethanol mixture with an aqueous or ethanolic solution of the bioactive agent at a temperature below the phase transition of at least one of the lipid components of the lipid and compositions produced by the method of the invention.

US Patent:

20040009126, Jan 15, 2004

Filed:

Mar 5, 2003

Appl. No.:

10/383173

Inventors:

Frank Pilkiewicz - Princeton Junction NJ, US
Lawrence Boni - Monmouth Junction NJ, US
Constance Mackinson - Skillman NJ, US
Joel Portnoff - Langhorne PA, US
Anthony Scotto - Washington Crossing PA, US
Fangjun Wu - Livingston NJ, US
Brian Miller - Mercerville NJ, US

Assignee:

Transave, Inc. - Monmouth Junction NJ

International Classification:

A61L009/04
A61K009/14

US Classification:

424/046000

Abstract:

An inhalation system comprising an antiinfective agent in particle form, the antiinfective agent being directed toward prevention and treatment of intracellular infection, and an inhalation device, and a method of use of the system.

US Patent:

20040101553, May 27, 2004

Filed:

Aug 4, 2003

Appl. No.:

10/634144

Inventors:

Jin Lee - Belle Mead NJ, US
Brian Miller - Mercerville NJ, US
Fangjun Wu - Livingston NJ, US
Lawrence Boni - Monmouth Junction NJ, US

Assignee:

Transave, Inc. - Monmouth Junction NJ

International Classification:

A61K033/24
A61K009/127

US Classification:

424/450000, 424/649000

Abstract:

A composition and process for making the composition, the composition comprising a liposome and active platinum compound, the liposome containing one or more lipids, with a high active platinum compound to lipid ratio.

US Patent:

20080160067, Jul 3, 2008

Filed:

Sep 5, 2007

Appl. No.:

11/899282

Inventors:

Albert Boeckh - Cumming GA, US
Mark D. Soll - Alpharetta GA, US
Robert P. Waranis - Annandale NJ, US
Fangjun Wu - Livingston NJ, US

International Classification:

A61K 9/68
A61K 31/40

US Classification:

424441, 514422

Abstract:

This document relates to formulations for combating bacterial infections in animals which provide for improved long-acting oral and injectable formulations for systemic delivery of antibiotics, which are designed to achieve high bioavailability.

US Patent:

20080187578, Aug 7, 2008

Filed:

Feb 7, 2008

Appl. No.:

12/027752

Inventors:

Jin K. Lee - Belle Mead NJ, US
Brian S. Miller - Mercerville NJ, US
Fangjun Wu - Livingston NJ, US
Lawrence T. Boni - Monmouth Junction NJ, US
Vladimir Malinin - Plainsboro NJ, US

Assignee:

Transave, Inc. - Monmouth Junction NJ

International Classification:

A61K 9/127
A61K 33/24
A61K 31/28

US Classification:

424450, 424649, 514492

Abstract:

One aspect of the disclosure relates to a new form of lipid-complexed active platinum compound, which allows for high concentrations of platinum compound in the composition. For example, the concentration of cisplatin in the composition is higher at room temperature, e.g., about greater than 1.2 mg/mL, compared to 1 mg/mL in aqueous solution. In one embodiment, the present invention is directed to a composition comprising a lipid-complexed active platinum compound, wherein the complex has a lipid to drug (L/D) ratio of less than about 1 by weight, e.g. about 0.10 to 1, wherein the lipid-complexed active platinum compound comprises at least one lipid and at least one active platinum compound. In other embodiments, wherein lipid-complexed active platinum compound has an average volume-weighted diameter of about 0.5 to about 20 microns. In still other embodiments, the composition further comprises a liposome. The liposome may comprise at least one lipid, and may further comprise at least one active platinum compound. The disclosure also relates to a pharmaceutical formulation comprising a lipid complexed active platinum compound and a pharmaceutically acceptable carrier or diluent. The pharmaceutical formulation may be formulated for inhalation or injection.

US Patent:

20020160039, Oct 31, 2002

Filed:

Dec 3, 2001

Appl. No.:

09/999191

Inventors:

Lawrence Boni - Monmouth Junction NJ, US
Fangjun Wu - Livingston NJ, US
Roy Fennimore - Lawrenceville NJ, US
Michael Batenjany - San Diego CA, US

Assignee:

BIOMIRA U.S.A., Inc.

International Classification:

A61K009/127
B65B001/00

US Classification:

424/450000, 264/004000

Abstract:

This invention provides a method of preparing large liposomes with high entrapment capacity for pharmaceutical substances. The method generally entails infusing a lipid/alcohol solution directly into an aqueous polymer solution. The resulting liposome, which may be incorporated with a pharmaceutical substance, typically consists of multilamellar vesicles that have an average size of about 1 to about 8 microns. The ratio of lipid to polymer, average molecular weight of the polymer, polymer concentration, ionic strength, and temperature of incubation are variables disclosed herein to control liposome size and incorporation of components and pharmaceutical substances.

US Patent:

20160263030, Sep 15, 2016

Filed:

Oct 12, 2015

Appl. No.:

14/881011

Inventors:

- Bridgewater NJ, US
Brian S. Miller - Mercerville NJ, US
Fangjun WU - Livingston NJ, US
Lawrence T. BONI - Monmouth Junction NJ, US
Vladimir MALININ - Plainsboro NJ, US

International Classification:

A61K 9/127
A61K 33/24

Abstract:

One aspect of the disclosure relates to a new fom1 of lipid-complexed active platinum compound, which allows for high concentrations of platinum compound in the composition. For example, the concentration of cisplatin in the composition is higher at room temperature, e.g., about greater than 1.2 mg/mL, compared to 1 mg/mL in aqueous solution. In one embodiment, the present invention is directed to a composition comprising a lipid-complexed active platinum compound, wherein the complex has a lipid to drug (L/D) ratio of less than about 1 by weight, e.g. about 0.10 to 1, wherein the lipid-complexed active platinum compound comprises at least one lipid and at least one active platinum compound. In other embodiments, wherein lipid-complexed active platinum compound has an average volume-weighted diameter of about 0.5 to about 20 microns. In still other embodiments, the composition further comprises a liposome. The liposome may comprise at least one lipid, and may further comprise at least one active platinum compound. The disclosure also relates to a pharmaceutical formulation comprising a lipid complexed active platinum compound and a pharmaceutically acceptable carrier or diluent. The pharmaceutical formulation may be formulated for inhalation or injection.